Clinic
Pain Treatment Centers of America, PLLC
Pain Treatment Centers of America, PLLC was paid $19.56M by Medicaid between Jan 2018 and Dec 2024, across 113 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoPAIN TREATMENT CENTERS OF AMERICA, PLLC
LITTLE ROCK, AR 72211
LITTLE ROCK, AR 72211
33aNPI1841619731assigned 04/08/2014
33bProvider typeMagnetic Resonance Imaging (MRI) Clinic/Center
28Total paid$19.56M
24GClaims1,180,230
24DCodes billed113
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Magnetic Resonance Imaging (MRI) Clinic/Center providers in Arkansas
Rank by total paid#1 of 5
Median peer was paid$11K
This provider vs. median1,769×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 97,513 | $2.22M | |
| 2019 | 209,354 | $3.93M | |
| 2020 | 159,524 | $2.42M | |
| 2021 | 160,356 | $2.47M | |
| 2022 | 178,675 | $2.66M | |
| 2023 | 191,077 | $3.36M | |
| 2024incomplete | 183,731 | $2.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 125,963 | 99,182 | $4.05M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 14% | 122,068 | 100,064 | $2.79M |
| 64636 | 11% | 3,170 | 2,255 | $2.21M | |
| 64635 | 9.2% | 4,097 | 2,879 | $1.80M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.5% | 39,316 | 29,778 | $684K |
| 80354 | 2.6% | 51,460 | 43,646 | $513K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.5% | 11,088 | 8,373 | $490K |
| 64493 | 2.4% | 6,105 | 3,712 | $473K | |
| 80373 | 2.3% | 47,624 | 40,060 | $446K | |
| 80372 | 2.2% | 48,366 | 41,153 | $424K | |
| 80369 | 2.1% | 51,439 | 43,620 | $420K | |
| 80348 | 2.1% | 44,841 | 37,817 | $411K |
101 more codes
| 80363 | 1.6% | 51,174 | $317K | |
| 80352 | 1.5% | 47,599 | $297K | |
| 80361 | 1.5% | 34,439 | $286K | |
| 80371 | 1.4% | 47,852 | $280K | |
| 80357 | 1.4% | 47,951 | $273K | |
| 80367 | 1.3% | 35,124 | $255K | |
| 80355 | 1.3% | 51,366 | $246K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.2% | 1,083 | $234K |
| 64494 | 1.2% | 5,848 | $227K | |
| 62323 | 1.1% | 1,787 | $216K | |
| 80359 | 1.1% | 31,949 | $210K | |
| 80360 | 1.0% | 35,665 | $205K | |
| 80338 | <1% | 32,098 | $182K | |
| 64495 | <1% | 4,050 | $169K | |
| 80366 | <1% | 32,089 | $158K | |
| 80358 | <1% | 14,943 | $131K | |
| 27096 | <1% | 670 | $123K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 12,622 | $117K |
| 80335 | <1% | 15,001 | $102K | |
| 80356 | <1% | 6,734 | $84K | |
| 80323 | <1% | 3,812 | $68K | |
| 80349 | <1% | 11,343 | $50K | |
| 80346 | <1% | 5,695 | $48K | |
| 80365 | <1% | 6,853 | $41K | |
| 80345 | <1% | 3,736 | $37K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 203 | $35K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,067 | $34K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 2,763 | $33K |
| 72141 | <1% | 151 | $32K | |
| 83992 | <1% | 5,056 | $27K | |
| 84403 | <1% | 2,834 | $27K | |
| 20610 | <1% | 937 | $26K | |
| 62321 | <1% | 157 | $24K | |
| 80324 | <1% | 3,371 | $21K | |
| 77002 | <1% | 885 | $17K | |
| 82607 | <1% | 2,992 | $16K | |
| 64451 | <1% | 207 | $16K | |
| 82746 | <1% | 2,922 | $15K | |
| 64634 | <1% | 16 | $15K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,542 | $14K |
| 82977 | <1% | 4,255 | $13K | |
| 80050 | General health panel | <1% | 766 | $13K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 859 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,013 | $10K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 563 | $8K |
| 64633 | <1% | 16 | $8K | |
| 83735 | <1% | 2,976 | $7K | |
| 99152 | <1% | 246 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,050 | $6K |
| 86140 | <1% | 2,898 | $5K | |
| 84100 | <1% | 2,978 | $5K | |
| 85027 | <1% | 2,051 | $4K | |
| 99072 | <1% | 9,361 | $4K | |
| 99205 | Prolong outpt/office vis | <1% | 42 | $4K |
| 64483 | <1% | 49 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,584 | $4K |
| 64490 | <1% | 52 | $3K | |
| 80321 | <1% | 922 | $3K | |
| 99406 | <1% | 262 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 37 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 688 | $2K |
| 62370 | <1% | 146 | $2K | |
| 64492 | <1% | 52 | $2K | |
| 64491 | <1% | 52 | $2K | |
| 64450 | <1% | 58 | $1K | |
| 64640 | <1% | 19 | $988.14 | |
| 96130 | <1% | 171 | $860.74 | |
| 62369 | <1% | 37 | $742.81 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 79 | $732.36 |
| 95886 | <1% | 15 | $723.94 | |
| 99454 | <1% | 160 | $723.89 | |
| J3490 | Unclassified drugs | <1% | 2,342 | $688.03 |
| 97162 | <1% | 42 | $660.15 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,489 | $531.27 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $498.79 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 382 | $456.51 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 472 | $424.96 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 123 | $382.53 |
| 80305 | <1% | 96 | $373.59 | |
| 99457 | <1% | 174 | $373.49 | |
| 80362 | <1% | 796 | $326.94 | |
| 99442 | <1% | 136 | $305.24 | |
| 76942 | <1% | 36 | $248.28 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 62 | $238.73 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 35 | $182.41 |
| 99443 | <1% | 40 | $157.05 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 53 | $155.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 391 | $65.50 |
| 96136 | <1% | 13 | $55.45 | |
| 99441 | <1% | 56 | $52.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 142 | $44.70 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,366 | $8.01 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,223 | $4.83 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 60 | $1.15 |
| G8913 | Patient documented not to have experienced a wrong site, wrong side, wrong patient, wrong procedure or wrong implant event | <1% | 612 | $0.03 |
| G8911 | Patient documented not to have experienced a fall within ambulatory surgical center | <1% | 614 | $0.03 |
| G8909 | Patient documented not to have received a burn prior to discharge | <1% | 614 | $0.03 |
| G8918 | Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis | <1% | 607 | $0.03 |
| G8915 | Patient documented not to have experienced a hospital transfer or hospital admission upon discharge from asc | <1% | 614 | $0.03 |
| 64454 | 0% | 13 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIDDIQUI, MERAJ (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Searcy Ambulatory Surgery Center LLC | Searcy, AR | $82K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.